Jonathan E. Rosenberg

Jonathan E. Rosenberg, MD is Chief of the Genitourinary Oncology Service and holds the Enno W. Ercklentz Chair in Medicine at Memorial Sloan Kettering Cancer Center. He is one of the world's foremost authorities on urothelial carcinoma, with a career defined by landmark clinical trials that have transformed the treatment of advanced bladder cancer. He was the global principal investigator for EV-301, the phase III trial demonstrating that enfortumab vedotin—a Nectin-4-directed antibody-drug conjugate—significantly improved overall survival compared to chemotherapy in platinum-pretreated, PD-1/PD-L1 inhibitor-refractory urothelial carcinoma, leading to full FDA approval. Subsequently, Dr. Rosenberg led the EV-302/KEYNOTE-869 trial evaluating enfortumab vedotin plus pembrolizumab in the first-line setting, which showed unprecedented response rates and survival outcomes that have shifted frontline bladder cancer therapy. He has also been instrumental in the clinical development of erdafitinib for FGFR-altered bladder cancer and has contributed foundational studies on cisplatin-eligibility criteria and platinum-based chemotherapy optimization. Dr. Rosenberg has published more than 300 peer-reviewed papers and is a frequently invited speaker at ASCO, ESMO, and the American Urological Association (AUA).